eFFECTOR Therapeutics Stock

effector.comHealthcareFounded: 2012Funding to Date: $152.08MM

eFFECTOR Therapeutics is a clinical-stage biopharmaceutical company focused on pioneering the discovery and development of a new class of oncology drugs known as selective translation regulators (STRs).

Register for Details

For more details on financing and valuation for eFFECTOR Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Enterprise Value (based on primary financings)

Powered by Forge Data
Enterprise Value

View Enterprise Value for eFFECTOR Therapeutics.

Register Today


Management Team

Stephen Worland Ph.D
Chief Executive Officer, President, Board Member & Co-Founder
Davide Ruggero Ph.D
Kevin Webster Ph.D
Senior Vice President of Cancer Biology
Alana McNulty
Chief Financial Officer
Debra Vallner Ph.D
Vice President of Development Operations
Kevan Shokat Ph.D
Co-Founder and Member of Scientific Advisory Board
Siegfried Reich Ph.D
Senior Vice President, Research & Co-Founder
Annette Matthies Ph.D
Vice President of Corporate Development
Jeremy Barton MD
Chief Medical Officer

Board Members

David Maki JD
Altitude Life Science Ventures
Ken Haas JD
Markus Goebel Ph.D
Novartis Venture Fund
Elaine Jones Ph.D
Pfizer Ventures
Laurence Lasky Ph.D
US Venture Partners
Stephen Worland Ph.D
Jonathan Root MD
US Venture Partners
KT Moortgat Ph.D
AbbVie Ventures
Simeon George MD
SR One

Other companies like eFFECTOR Therapeutics in the Healthcare sector

Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation
Last Round Est. Valuation


Locust Walk Acquisition Corp. (NASDAQ: LWAC) (“LWAC” or the “Company”), a special purpose acquisition company, announced today that the Company’s stockholders have approved all proposals related to the previously announced business combination (the “Business Combination”) with eFFECTOR Therapeutics, Inc. (“eFFECTOR”) at a special meeting of stockholders held on August 24, 2021. Approximately 93.2% of the votes cast at the meeting on the Business Combination proposal, representing approximately 71.7% of LWAC’s outstanding shares, voted to approve the Business Combination.
San Diego’s Effector Therapeutics, a five-year-old cancer drug developer, has raised $38.6 million in new venture capital funding. The Series C financing,
/PRNewswire/ -- eFFECTOR Therapeutics, Inc., a biopharmaceutical company developing selective translation regulators for the treatment of cancer, today...